Literature DB >> 27830539

Primary autoimmune myelofibrosis: a case report and review of the literature.

Yasmin Abaza1, C Cameron Yin2, Carlos E Bueso-Ramos2, Sa A Wang2, Srdan Verstovsek3.   

Abstract

Autoimmune myelofibrosis is a rare, distinct clinicopathological entity that can occur in isolation (primary) or in association with systemic autoimmune disorders (secondary), such as systemic lupus erythematosus and Sjogren's syndrome. This disease is characterized by isolated or combined chronic cytopenias associated with autoimmune phenomena and bone-marrow fibrosis. Due to the rarity of this disease, patients are frequently misdiagnosed as having primary myelofibrosis, the most common form of bone-marrow fibrosis. Distinguishing between both disease entities is essential given the drastic therapeutic and prognostic differences between both disorders. We report a case of primary autoimmune myelofibrosis presenting with severe isolated anemia refractory to multiple lines of therapy. This patient was initially misdiagnosed as primary myelofibrosis. The absence of the characteristic features of primary myelofibrosis and the lack of a clonal abnormality on cytogenetic and molecular studies, particularly JAK2, CALR, and MPL mutation analyses, confirmed the absence of an aberrant neoplastic process. Furthermore, the presence of monoclonal T-cell receptor gamma gene rearrangements delineated the presence of an autoimmune disorder supporting our diagnosis of primary autoimmune myelofibrosis.

Entities:  

Keywords:  Anemia; Autoimmunity; Bone marrow fibrosis; Clonality; Cytokine; Myelofibrosis

Mesh:

Year:  2016        PMID: 27830539     DOI: 10.1007/s12185-016-2129-5

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  17 in total

1.  Comparison of traditional methods and mitogen-stimulated direct antiglobulin test for detection of anti-red blood cell autoimmunity.

Authors:  Wilma Barcellini; Nicoletta Revelli; Francesca Guia Imperiali; Maria Antonietta Villa; Maria Cristina Manera; Cinzia Paccapelo; Anna Zaninoni; Alberto Zanella
Journal:  Int J Hematol       Date:  2010-05-08       Impact factor: 2.490

Review 2.  Bone marrow fibrosis: pathophysiology and clinical significance of increased bone marrow stromal fibres.

Authors:  David J Kuter; Barbara Bain; Ghulam Mufti; Adam Bagg; Robert P Hasserjian
Journal:  Br J Haematol       Date:  2007-11       Impact factor: 6.998

Review 3.  Myelofibrosis with myeloid metaplasia.

Authors:  A Tefferi
Journal:  N Engl J Med       Date:  2000-04-27       Impact factor: 91.245

4.  European consensus on grading bone marrow fibrosis and assessment of cellularity.

Authors:  Jürgen Thiele; Hans Michael Kvasnicka; Fabio Facchetti; Vito Franco; Jon van der Walt; Attilio Orazi
Journal:  Haematologica       Date:  2005-08       Impact factor: 9.941

5.  Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel.

Authors:  Ayalew Tefferi; Juergen Thiele; Attilio Orazi; Hans Michael Kvasnicka; Tiziano Barbui; Curtis A Hanson; Giovanni Barosi; Srdan Verstovsek; Gunnar Birgegard; Ruben Mesa; John T Reilly; Heinz Gisslinger; Alessandro M Vannucchi; Francisco Cervantes; Guido Finazzi; Ronald Hoffman; D Gary Gilliland; Clara D Bloomfield; James W Vardiman
Journal:  Blood       Date:  2007-05-08       Impact factor: 22.113

Review 6.  Autoimmune myelofibrosis: an update on morphologic features in 29 cases and review of the literature.

Authors:  Maria E Vergara-Lluri; Caroline I Piatek; Vinod Pullarkat; Imran N Siddiqi; Casey O'Connell; Donald I Feinstein; Russell K Brynes
Journal:  Hum Pathol       Date:  2014-08-13       Impact factor: 3.466

7.  Phenotypic differences between healthy effector CTL and leukemic LGL cells support the notion of antigen-triggered clonal transformation in T-LGL leukemia.

Authors:  Marcin W Wlodarski; Zachary Nearman; Anna Jankowska; Nina Babel; Jennifer Powers; Patrick Leahy; Hans-Dieter Volk; Jaroslaw P Maciejewski
Journal:  J Leukoc Biol       Date:  2007-12-17       Impact factor: 4.962

8.  Primary autoimmune myelofibrosis: definition of a distinct clinicopathologic syndrome.

Authors:  Vinod Pullarkat; Randall D Bass; Jerald Z Gong; Donald I Feinstein; Russell K Brynes
Journal:  Am J Hematol       Date:  2003-01       Impact factor: 10.047

Review 9.  Autoimmune myelofibrosis: report of three cases and review of the literature.

Authors:  Rita Rizzi; Domenico Pastore; Arcangelo Liso; Grazia M Liuzzi; Anna M Dalena; Giorgina Specchia; Rosalia Ricco; Vincenzo Liso
Journal:  Leuk Lymphoma       Date:  2004-03

Review 10.  Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1.

Authors:  A Tefferi
Journal:  Leukemia       Date:  2010-04-29       Impact factor: 11.528

View more
  3 in total

1.  Primary autoimmune myelofibrosis: A case report in a child.

Authors:  Zufit Hexner-Erlichman; Joanne Yacobovich; Philippe Trougouboff; Moran Avraham-Kelbert; Harel Eitam; Ronen Spiegel; Shay Yeganeh; Carina Levin
Journal:  EJHaem       Date:  2020-06-28

2.  Clinical Utility of Next-generation Sequencing in the Management of Myeloproliferative Neoplasms: A Single-Center Experience.

Authors:  Waleed Alduaij; Caroline J McNamara; Andre Schuh; Andrea Arruda; Mahadeo Sukhai; Nisha Kanwar; Mariam Thomas; Jay Spiegel; James A Kennedy; Tracy Stockley; Hubert Tsui; Rebecca Devlin; Hassan Sibai; Dawn Maze; Aaron Schimmer; Karen Yee; Steven Chan; Suzanne Kamel-Reid; Vikas Gupta
Journal:  Hemasphere       Date:  2018-05-04

3.  Sjögren's syndrome manifesting as clinicopathological features of TAFRO syndrome: A case report.

Authors:  Shino Fujimoto; Hiroshi Kawabata; Nozomu Kurose; Haruka Kawanami-Iwao; Tomoyuki Sakai; Takafumi Kawanami; Yoshimasa Fujita; Toshihiro Fukushima; Yasufumi Masaki
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.